ES2969982T3 - Compuestos de pteridinona y usos de los mismos - Google Patents
Compuestos de pteridinona y usos de los mismos Download PDFInfo
- Publication number
- ES2969982T3 ES2969982T3 ES19726791T ES19726791T ES2969982T3 ES 2969982 T3 ES2969982 T3 ES 2969982T3 ES 19726791 T ES19726791 T ES 19726791T ES 19726791 T ES19726791 T ES 19726791T ES 2969982 T3 ES2969982 T3 ES 2969982T3
- Authority
- ES
- Spain
- Prior art keywords
- ring
- cancer
- nitrogen
- partially unsaturated
- oxygen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862661744P | 2018-04-24 | 2018-04-24 | |
| PCT/US2019/028604 WO2019209757A1 (en) | 2018-04-24 | 2019-04-23 | Pteridinone compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2969982T3 true ES2969982T3 (es) | 2024-05-23 |
Family
ID=66655428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES19726791T Active ES2969982T3 (es) | 2018-04-24 | 2019-04-23 | Compuestos de pteridinona y usos de los mismos |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11059826B2 (https=) |
| EP (1) | EP3784669B1 (https=) |
| JP (2) | JP7479293B2 (https=) |
| CN (1) | CN112218865B (https=) |
| AR (1) | AR114828A1 (https=) |
| AU (1) | AU2019257651B2 (https=) |
| CA (1) | CA3097774A1 (https=) |
| ES (1) | ES2969982T3 (https=) |
| IL (1) | IL278122B2 (https=) |
| TW (1) | TWI884914B (https=) |
| WO (1) | WO2019209757A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2969982T3 (es) * | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
| WO2020010451A1 (en) * | 2018-07-10 | 2020-01-16 | Trillium Therapeutics Inc. | Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists |
| SG11202107614PA (en) | 2019-01-18 | 2021-08-30 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
| AU2020209216A1 (en) | 2019-01-18 | 2021-08-26 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| PL3919491T3 (pl) * | 2019-01-29 | 2025-10-20 | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. | Inhibitor akt |
| EP4045498B1 (en) * | 2019-10-14 | 2025-12-03 | The Regents of the University of California | Broad spectrum anti-cancer compounds |
| US20230322767A1 (en) | 2020-07-29 | 2023-10-12 | Bayer Aktiengesellschaft | Aryl substituted pyrrolo-pyridinones and therapeutic uses thereof |
| CN117088877A (zh) * | 2020-10-28 | 2023-11-21 | 杭州阿诺生物医药科技有限公司 | 一种高活性Wnt通路抑制剂化合物 |
| TW202334157A (zh) * | 2022-01-29 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | 一種Ｗｎｔ通路抑制劑化合物 |
| TW202333697A (zh) * | 2022-01-30 | 2023-09-01 | 大陸商杭州阿諾生物醫藥科技有限公司 | Ｗｎｔ通路抑制劑化合物 |
| CN114436918B (zh) * | 2022-02-23 | 2023-05-23 | 郑州大学 | 环丁-1-烯胺类化合物及其制备方法和在药物中的应用 |
| CN117396482B (zh) * | 2022-07-28 | 2026-02-27 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
| WO2024022365A1 (zh) * | 2022-07-28 | 2024-02-01 | 杭州阿诺生物医药科技有限公司 | 一种Wnt通路抑制剂化合物 |
| US20240217951A1 (en) * | 2022-09-23 | 2024-07-04 | Astrazeneca Ab | Pcsk9 inhibitors and methods of use thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| EP1389617B1 (en) | 2001-04-27 | 2007-01-03 | Zenyaku Kogyo Kabushiki Kaisha | Heterocyclic compound and antitumor agent containing the same as active ingredient |
| PT1427730E (pt) | 2001-09-04 | 2006-11-30 | Boehringer Ingelheim Pharma | Novas di-hidropteridinonas, processo para sua preparação e sua utilização como medicamento |
| US6806272B2 (en) * | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
| KR20070087266A (ko) | 2003-04-03 | 2007-08-28 | 세마포르 파머슈티컬즈, 아이엔씨. | 피아이-3 키나아제 억제제 프로드러그 |
| CN1832939B (zh) | 2003-05-30 | 2010-04-28 | 杰明X医药品加拿大公司 | 用于治疗癌症或病毒病的三杂环化合物、组合物和方法 |
| US7173015B2 (en) | 2003-07-03 | 2007-02-06 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
| SI2612862T1 (sl) | 2004-05-13 | 2017-04-26 | Icos Corporation | Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta |
| DE102004029784A1 (de) * | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
| AU2011226830A1 (en) * | 2004-08-14 | 2011-10-13 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| US20060058311A1 (en) | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
| EP1632493A1 (de) * | 2004-08-25 | 2006-03-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| DE602006010979D1 (de) | 2005-01-19 | 2010-01-21 | Rigel Pharmaceuticals Inc | Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen |
| EP1888550B1 (en) | 2005-05-12 | 2014-06-25 | AbbVie Bahamas Ltd. | Apoptosis promoters |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
| WO2007014838A1 (en) * | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Dihydropteridinones in the treatment of respiratory diseases |
| BRPI0617162B8 (pt) | 2005-10-07 | 2021-05-25 | Exelixis Inc | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos |
| CN103626742B (zh) | 2005-11-01 | 2017-04-26 | 塔格根公司 | 激酶的联-芳基间-嘧啶抑制剂 |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| MX2008013578A (es) | 2006-04-26 | 2009-03-23 | Hoffmann La Roche | Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k). |
| BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
| HRP20151386T1 (hr) | 2007-03-12 | 2016-02-26 | Ym Biosciences Australia Pty Ltd | Fenil aminopirimidinski spojevi i njihova primjena |
| WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
| PE20090717A1 (es) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| US8158616B2 (en) | 2008-03-11 | 2012-04-17 | Incyte Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| US8865716B2 (en) | 2012-02-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Dihydropteridinones II |
| JP6052527B2 (ja) | 2013-02-21 | 2016-12-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ジヒドロプテリジノンｉ |
| EP2958918B1 (en) | 2013-02-21 | 2016-12-07 | Boehringer Ingelheim International GmbH | Dihydropteridinones ii |
| WO2015117055A1 (en) * | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Dihydropteridinone derivatives and uses thereof |
| WO2015193229A1 (de) | 2014-06-19 | 2015-12-23 | Bayer Pharma Aktiengesellschaft | Bet-proteininhibitorische 1,4-dihydropyrido[3,4-b]pyrazinone mit meta-substituierter aromatischer amino- oder ethergruppe |
| US10702527B2 (en) * | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| CN105801582A (zh) * | 2016-04-12 | 2016-07-27 | 合肥工业大学 | 一类新型二氢蝶啶酮类衍生物及其制备方法和在医药上的用途 |
| ES2969982T3 (es) * | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
-
2019
- 2019-04-23 ES ES19726791T patent/ES2969982T3/es active Active
- 2019-04-23 US US16/391,407 patent/US11059826B2/en active Active
- 2019-04-23 IL IL278122A patent/IL278122B2/en unknown
- 2019-04-23 EP EP19726791.7A patent/EP3784669B1/en active Active
- 2019-04-23 CN CN201980035546.1A patent/CN112218865B/zh active Active
- 2019-04-23 AR ARP190101061A patent/AR114828A1/es unknown
- 2019-04-23 TW TW108114117A patent/TWI884914B/zh active
- 2019-04-23 JP JP2020559365A patent/JP7479293B2/ja active Active
- 2019-04-23 AU AU2019257651A patent/AU2019257651B2/en active Active
- 2019-04-23 CA CA3097774A patent/CA3097774A1/en active Pending
- 2019-04-23 WO PCT/US2019/028604 patent/WO2019209757A1/en not_active Ceased
-
2021
- 2021-03-01 US US17/188,132 patent/US11572364B2/en active Active
-
2022
- 2022-12-05 US US18/075,270 patent/US12384790B2/en active Active
-
2023
- 2023-06-15 JP JP2023098522A patent/JP2023116712A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112218865B (zh) | 2024-03-12 |
| US12384790B2 (en) | 2025-08-12 |
| IL278122A (en) | 2020-11-30 |
| US20190322673A1 (en) | 2019-10-24 |
| US11059826B2 (en) | 2021-07-13 |
| US20230312587A1 (en) | 2023-10-05 |
| WO2019209757A1 (en) | 2019-10-31 |
| US20220363685A1 (en) | 2022-11-17 |
| IL278122B1 (en) | 2023-09-01 |
| JP2023116712A (ja) | 2023-08-22 |
| JP7479293B2 (ja) | 2024-05-08 |
| TW202010744A (zh) | 2020-03-16 |
| US11572364B2 (en) | 2023-02-07 |
| EP3784669A1 (en) | 2021-03-03 |
| AU2019257651B2 (en) | 2023-05-25 |
| CA3097774A1 (en) | 2019-10-31 |
| TWI884914B (zh) | 2025-06-01 |
| EP3784669B1 (en) | 2023-10-25 |
| JP2021522237A (ja) | 2021-08-30 |
| IL278122B2 (en) | 2024-01-01 |
| AR114828A1 (es) | 2020-10-21 |
| CN112218865A (zh) | 2021-01-12 |
| AU2019257651A1 (en) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2969982T3 (es) | Compuestos de pteridinona y usos de los mismos | |
| ES2870920T3 (es) | Inhibidores de CXCR4 y usos de los mismos | |
| US20240018118A1 (en) | Tricyclic compounds to degrade neosubstrates for medical therapy | |
| JP6994767B2 (ja) | Ｃｘｃｒ４阻害剤およびその使用 | |
| TW202108571A (zh) | Tead抑制劑及其用途 | |
| KR20220034739A (ko) | Tead 억제제 및 이의 용도 | |
| KR20230172548A (ko) | Mek 억제제 및 이의 용도 | |
| WO2022120355A1 (en) | Tead degraders and uses thereof | |
| US20240092779A1 (en) | Usp1 inhibitors and uses thereof | |
| CA3098335A1 (en) | Antiproliferation compounds and uses thereof | |
| EP3846793A1 (en) | Eif4e inhibitors and uses thereof | |
| WO2023173057A1 (en) | Mek inhibitors and uses thereof | |
| JP2022538138A (ja) | Ｃｘｃｒ４阻害剤およびその使用 | |
| HK40050670A (en) | Substituted piperidines as cxcr4-inhibitors | |
| EA047483B1 (ru) | Ингибиторы tead и их применения | |
| HK40006048B (en) | Cxcr4 inhibitors and uses thereof | |
| HK40006048A (en) | Cxcr4 inhibitors and uses thereof |